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This practical tool is now at the stage that it will be 
evaluated clinically in each centre. By now several centres 
have experience with image guided adaptive brachytherapy 
in limited numbers of patients with vaginal cancer. To gain 
more knowledge from this already existing experience a 
retrospective database has been established with inclusion of 
approximately 90 patients that have been treated with CT or 
MRI guided brachytherapy. Although different target concepts 
have been used, this cohort will allow for analysis of disease 
control, prognostic factors and descriptive analysis of the 
radiotherapy related parameters in a more contemporary 
series. A future goal will be establishment of a prospective 
multicentre database with inclusion of patients treated with 
a common target concept.  
During this presentation existing results for radiotherapy in 
vaginal cancer will be reviewed, followed by an overview of 
the work that has been performed to introduce image guided 
adaptive brachytherapy in primary vaginal cancer within the 
GEC ESTRO GYN group. 
 
Symposium: Quantitative imaging to individualise 
radiotherapy  
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In this presentation the possibilities for image quantification 
for tissue characterization will be discussed that go beyond 
quantification of Hounsfield Units for CT or SUV for PET 
imaging. Standardization aspects of advanced imaging 
techniques are important for reliable and robust 
quantification. Besides the image acquisition, an equally 
important part is validation of the used image analysis 
techniques. Especially for textural feature calculations (e.g. 
radiomics) this is not a trivial task and may require some 
more detailed guidelines for acquisition, segmentation, 
analysis and reporting of results. The entire pipeline from 
image acquisition to analysis should be designed to allow 
interchangeable and robust results between e.g. institutes, 
software packages and imaging equipment. This presentation 
will illustrate the possibilities of advanced image 
quantification, concepts and techniques with clinical 
examples: Radiomics of tumours are currently investigated to 
predict local control, metastasis patterns or survival of 
patients, whereas advanced image quantification of normal 
tissues may allow better prediction of patients prone to 
toxicity. 
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Solid tumors may be heterogeneous with respect to 
radiosensitivity, and a homogeneous tumor dose is thus not 
always optimal. Thus, medical images of radiobiological 
relevance may be used to guide focal irradiation of tumors. 
Tumor control probability (TCP) modeling may be useful for 
optimizing dose painting treatment plans and for estimating 
the effect of such therapeutic strategies.  
Both magnetic resonance imaging and positron emission 
tomography may provide voxel-by-voxel maps potentially 
reflecting tumor aggressiveness and radioresistance. The talk 
will elaborate on the biological relevance of theses imaging 
approaches and their pros and cons in terms of radiotherapy 
planning. Then, from the voxelwise mapping of tumor 
radiosensitivity, proposed frameworks for the tumor control 
probability modelling will be presented. Both data-driven and 
model-driven approaches are discussed. Furthermore, the 
potential use of TCP modelling in dose painting will be 
elaborated. Also, the concept of ‘LET’ painting in particle 
therapy will be highlighted. 
In concluding, the current and future role of image based 
TCP modelling will be discussed, seen together with both 
advances in biologic imaging and in radiotherapy delivery and 
guidance techniques. 
 
SP-0208  
Validation of imaging with histology: implications for dose 
prescriptions 
G. Ghobadi
1Netherlands Cancer Institute Antoni van Leeuwenhoek 
Hospital, Radiotherapy Department, Amsterdam, The 
Netherlands 
1, J. De Jong2, B.G. Hollman1, B. Van Triest1, H.G. 
Van der Poel3, C. Vens4, U.A. Van der Heide1 
2Netherlands Cancer Institute Antoni van Leeuwenhoek 
Hospital, Pathology Department, Amsterdam, The 
Netherlands 
3Netherlands Cancer Institute Antoni van Leeuwenhoek 
Hospital, Urology Department, Amsterdam, The Netherlands 
4Netherlands Cancer Institute Antoni van Leeuwenhoek 
Hospital, Division of Biological Stress Response, Amsterdam, 
The Netherlands 
 
In this era, image-guided radiotherapy provides the 
technology to modulate dose based on the variation in 
radiation sensitivity within cancer of the prostate. This raises 
the question what to irradiate and to which dose. Here, 
functional imaging techniques play an essential role. Multi-
parametric (mp) MRI, consisting of T2-weighted, diffusion-
weighted and dynamic contrast-enhanced MRI is a key 
element in the detection of prostate cancer, and is 
increasingly used for delineation of tumors inside the 
prostate gland. Validation with histopathology however shows 
that tumor detection and particularly tumor delineation is 
challenging. Prostate cancer is often multifocal and small 
lesions (<0.5cm3) are often missed. Tumor sub-volumes with 
low cell and microvessel density that resemble healthy tissue 
are also difficult to find with mp-MRI.The most aggressive 
parts of the tumors, containing high cell and microvessel 
density and a higher Gleason score, are more likely to be 
detected. The heterogeneity in the histopathology of 
prostate cancer together with the limitations of mpMRI in 
detecting small satellites has implications for dose 
prescriptions in radiotherapy. We therefore evaluated the 
potential impact of dose differentiation on the tumor control 
probability (TCP) in prostate radiotherapy using 
histopathological properties of prostate tumors. We defined 
GTV and CTV based on tumor volumes on H&E stained slices 
from prostatectomy specimen of 25 patients. Each patients’ 
TCP was simulated taking into account differences in the cell 
numbers (N0) and Gleason Scores (GS). We further evaluated 
the assumption that these tumors all have the same 
radiosensitivity, or that radiosensitivity decreases with 
increasing Gleason grade. Our results demonstrate feasible 
dose differentiations between GTV and CTV based on the 
heterogeneity in the histopathology of prostate tumors and 
the impact on the TCP of the patient population. We will 
further discuss the different GTV-CTV dose differentiations 
considering heterogeneity only in the number of tumor cells 
or also in the radiosensitivity, based on Gleason grade. 
Further studies in carefully designed clinical trials are needed 
to determine the effect of heterogeneous radiosensitivity on 
the response of individual patients to different regimes of 
radiotherapy. 
 
Proffered Papers: Physics 5: Intra-fraction motion 
management I  
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Purpose or Objective: Intrafraction motion is a challenge for 
accurate delivery of stereotactic body radiation therapy 
(SBRT) in the liver. Real-time treatment adaptation (gating, 
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tracking) may mitigate the detrimental effects of motion, but 
requires reliable target motion monitoring. On a conventional 
linac, monitoring can be obtained by intrafraction kilovoltage 
monitoring (KIM) using continuous imaging of implanted 
fiducials with a standard gantry-mounted x-ray imager. 
However, KIM adds imaging dose, is incompatible with large 
couch rotation, and KIM images suffer from MV scatter onto 
the kV imager. This study investigates the use of external 
monitoring combined with sparse kV imaging during beam 
pauses to overcome KIM limitations. 
 
Material and Methods: Six patients with 2-3 implanted gold 
markers received three fraction liver SBRT on a conventional 
linac. A setup CBCT was acquired with simultaneous 
recording of the motion of an external marker block on the 
abdomen (Fig. A). The 3D marker motion during the CBCT 
was estimated at 15Hz from the 2D motion in the CBCT 
projections and used to establish an external correlation 
model (ECM) of the internal marker motion INT(t) in each 
direction (RL, SI, AP) as a function of the external marker 
block motion EXT(t): INT(t) = A·EXT(t) + B·EXT(t-τ) +C, where 
A, B, C are coefficients and τ is a time constant. During 
treatment delivery, INT(t) was estimated from the external 
motion at 20Hz, while MV-scatter-free kV images were 
acquired every 3s during beam pauses. INT(t) was estimated 
from the ECM of the CBCT without any model update and 
with updates of the coefficient CSI by use of the first image 
of each treatment field. Post-treatment, the 3D marker 
positions were estimated for each intra-treatment kV image 
and used as ground truth to quantify the root mean square 
error (rmse) of the INT(t) estimations.  
 
Results: Figs. B-C compare the estimated INT(t) with and 
without model updates with the ground truth positions in 
intra-treatment kV images at one fraction. Table 1 shows the 
mean rmse for all fractions. ECM updates more than halved 
the SI rmse. Substantial internal cranial baseline drift up to 7 
mm (mean 1.4 mm) occurred between the setup CBCT and 
the last field without a similar drift for the external 
surrogate, illustrating the need for intra-treatment ECM 
updates.  
 
 
 
 
Conclusion: A correlation model between external surrogate 
motion and internal liver motion was established on a 
conventional linac from pre-treatment CBCT projections and 
used to estimate the intra-treatment target positions with 
and without model update. A simple update based on only 
one kV image per field substantially improved the 
localization accuracy. Real-time update of the model in all 3 
motion directions is currently being developed and is 
expected to further improve the localization accuracy. The 
proposed method increases the versatility and reduces the 
imaging dose compared to current clinical KIM 
implementations. 
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Purpose or Objective: Rotational radiotherapy IMRT (VMAT) 
has shown superior delivery efficiency with similar overall 
treatment plan quality compared to conventional IMRT. For 
lung treatments intra-fractional tumor motion is a major 
source of uncertainty in dose application leading to the 
enlargement of the PTV margins and possibly to increased 
dose delivery to OARs. Motion management by tracking the 
tumor using intra-fractional kV planar images has the 
potential to reduce position uncertainty and reduce the PTV 
margins. The challenge for rotational treatments is the poor 
tumor visibility at certain gantry angles. In this work we 
investigate the feasibility of delivering VMAT treatments 
using only partial arcs where the tumor is well visible and 
therefore tracking is feasible. 
 
Material and Methods: For our study we used the x-ray 
images acquired for CBCT reconstruction from five patients 
with NSCLC undergoing hypo-fractionated SBRT treatment (3 
fractions of 13.5Gy prescribed to the 65% isodose). These x-
rays are comparable to kV fluoroscopy images acquired 
during a VMAT treatment. For each patient the evaluation 
consisted of two steps: first real-time 2D/3D registration was 
used to track the tumor location on each of the x-rays from 
the CBCT acquisition. We determined the gantry angle 
intervals for which it was possible to track the tumor by 
comparing registration results with manually annotated 
diaphragm motion. Second, VMAT plans were created for 
partial arcs chosen depending on the anatomy and tumor 
location (U=unlimited) for a PTV based on an ITV approach 
(ITV plus 4mm margin) and for the limited partial arcs where 
the tumor tracking worked (L=limited) for a PTV based on the 
midventilation CTV (5mm margin). The L partial arc plans 
were evaluated using the U plans as benchmark. 
 
Results: For all cases is was possible to track the tumor in 
two arcs of about 90 degrees, typically with imaging around 
anterior-posterior (AP) or posterior-anterior (PA) projections. 
For patient 5 it was possible to track the tumor in all 
projections. In terms of plan quality, a target coverage of at 
least 99% to the 65% isodose was aimed for and could be 
achieved for all the U plans and for all the L plans except for 
one, where the available angle range led to an unfavorable 
dose distribution, which would be clinically not acceptable. 
Therefore this patient was omitted for further data 
evaluation. Table 1 summarizes the tracking angles and the 
DVH parameters. Figure 1 shows example tracking results and 
obtained plans for one patient. 
